GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AstraZeneca PLC (NAS:AZN) » Definitions » E10

AstraZeneca (AstraZeneca) E10 : $1.12 (As of Dec. 2023)


View and export this data going back to 1993. Start your Free Trial

What is AstraZeneca E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

AstraZeneca's adjusted earnings per share data for the three months ended in Dec. 2023 was $0.310. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $1.12 for the trailing ten years ended in Dec. 2023.

During the past 12 months, AstraZeneca's average E10 Growth Rate was 12.00% per year. During the past 3 years, the average E10 Growth Rate was -5.20% per year. During the past 5 years, the average E10 Growth Rate was -9.10% per year. During the past 10 years, the average E10 Growth Rate was -8.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of AstraZeneca was 77.50% per year. The lowest was -26.20% per year. And the median was 0.50% per year.

As of today (2024-04-25), AstraZeneca's current stock price is $75.03. AstraZeneca's E10 for the quarter that ended in Dec. 2023 was $1.12. AstraZeneca's Shiller PE Ratio of today is 66.99.

During the past 13 years, the highest Shiller PE Ratio of AstraZeneca was 75.22. The lowest was 4.62. And the median was 23.60.


AstraZeneca E10 Historical Data

The historical data trend for AstraZeneca's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AstraZeneca E10 Chart

AstraZeneca Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.52 1.42 1.11 0.95 1.12

AstraZeneca Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.95 1.00 1.07 1.03 1.12

Competitive Comparison of AstraZeneca's E10

For the Drug Manufacturers - General subindustry, AstraZeneca's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AstraZeneca's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AstraZeneca's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where AstraZeneca's Shiller PE Ratio falls into.



AstraZeneca E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, AstraZeneca's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0.31/130.0000*130.0000
=0.310

Current CPI (Dec. 2023) = 130.0000.

AstraZeneca Quarterly Data

per share eps CPI Adj_EPS
201403 0.200 99.300 0.262
201406 0.315 99.800 0.410
201409 0.100 100.000 0.130
201412 -0.125 99.900 -0.163
201503 0.220 99.600 0.287
201506 0.275 100.100 0.357
201509 0.300 100.200 0.389
201512 0.315 100.400 0.408
201603 0.255 100.400 0.330
201606 -0.001 101.000 -0.001
201609 0.400 101.500 0.512
201612 0.725 102.200 0.922
201703 0.210 102.700 0.266
201706 0.190 103.500 0.239
201709 0.270 104.300 0.337
201712 0.515 105.000 0.638
201803 0.135 105.100 0.167
201806 0.135 105.900 0.166
201809 0.170 106.600 0.207
201812 0.410 107.100 0.498
201903 0.235 107.000 0.286
201906 0.045 107.900 0.054
201909 0.115 108.400 0.138
201912 0.120 108.500 0.144
202003 0.295 108.600 0.353
202006 0.290 108.800 0.347
202009 0.245 109.200 0.292
202012 0.390 109.400 0.463
202103 0.590 109.700 0.699
202106 0.210 111.400 0.245
202109 -0.550 112.400 -0.636
202112 -0.110 114.700 -0.125
202203 0.125 116.500 0.139
202206 0.115 120.500 0.124
202209 0.525 122.300 0.558
202212 0.290 125.300 0.301
202303 0.580 126.800 0.595
202306 0.585 129.400 0.588
202309 0.440 130.100 0.440
202312 0.310 130.000 0.310

Add all the adjusted EPS together and divide 10 will get our e10.


AstraZeneca  (NAS:AZN) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

AstraZeneca's Shiller P/E Ratio of today is calculated as

Shiller PE Ratio=Share Price/E10
=75.03/1.12
=66.99

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Shiller P/E Ratio of AstraZeneca was 75.22. The lowest was 4.62. And the median was 23.60.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


AstraZeneca E10 Related Terms

Thank you for viewing the detailed overview of AstraZeneca's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


AstraZeneca (AstraZeneca) Business Description

Address
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, GBR, CB2 0AA
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology and rare diseases. The majority of sales come from international markets with the United States representing close to one third of its revenue.

AstraZeneca (AstraZeneca) Headlines

From GuruFocus